Neurocrine Biosciences | Capital Ordinaire



Ordinary Share Capital Changement Date
AbbVie USD 18M 0 2024-12
Acadia Pharmaceuticals USD 167.36M 167.35M 2025-06
Agios Pharmaceuticals USD 58.04M 57.96M 2025-06
ALKERMES USD 165.05M 163.25M 2025-06
Alnylam Pharmaceuticals USD 130.98M 129.67M 2025-06
Amgen USD 538M 33.04B 2025-06
Biogen USD 146.6M 146.5M 2025-06
BioMarin Pharmaceutical USD 192M 191.81M 2025-06
Cytokinetics USD 119.6M 119.48M 2025-06
Dynavax Technologies USD 117.23M 117.11M 2025-06
Exelixis USD 270.13M 269.86M 2025-07
Gilead Sciences USD 1.24B 3M 2025-06
Halozyme Therapeutics USD 117.62M 117.5M 2025-06
Incyte USD 194.12M 193.93M 2025-06
Ionis Pharmaceuticals USD 159.2M 159.04M 2025-06
Neurocrine Biosciences USD 99M 0 2025-06
Pfizer USD 5.68B 5.2B 2025-06
Prothena USD 538K 0 2024-12
Regeneron Pharmaceuticals USD 106.4M 106.4M 2025-06
Repligen USD 562K 1000 2025-03
Sarepta Therapeutics USD 97.71M 97.7M 2025-06
Teva Pharmaceutical Industries USD 1.15B 1.09B 2025-06
Ultragenyx Pharmaceutical USD 96.35M 2.45M 2025-06
Vertex Pharmaceuticals USD 256.3M 253.7M 2025-06


Neurocrine Biosciences Capital Ordinaire - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Aug 2025.